Enlivex Ltd
1BT
Company Profile
Business description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Contact
14 Einstein Street
Weizmann Science Park
Ness Ziona7403618
ISRT: +972 86328500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,925.60 | 28.50 | -0.32% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,499.27 | 152.87 | -0.31% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 26,291.11 | 514.58 | 2.00% |
| NASDAQ | 25,114.44 | 222.13 | 0.89% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,019.28 | 19.92 | -0.15% |
| S&P 500 | 7,230.12 | 21.11 | 0.29% |
| S&P/ASX 200 | 8,697.10 | 28.50 | -0.33% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |